We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Insulet Corporation | NASDAQ:PODD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.05 | 1.75% | 177.48 | 177.44 | 177.49 | 177.635 | 174.37 | 175.51 | 230,286 | 18:56:38 |
From May 2021 to May 2024
By Colin Kellaher
Shares of Insulet Corp. rose nearly 10% on Friday after the medical-device company won U.S. Food and Drug Administration approval for its Omnipod 5 automated insulin-delivery system for individuals ages 6 and older with type 1 diabetes.
The FDA nod represents a meaningful milestone for Insulet, said analysts at Citi, who noted that the Acton, Mass., company and its investors have been waiting for a green light for almost a year.
Citi said it believes the Omnipod 5, which is the first tubeless automated insulin-delivery system that integrates with DexCom Inc.'s G6 continuous glucose monitoring system and a compatible smartphone, will be very well received, and the analysts reiterated their buy rating on the stock.
Insulet shares were recently changing hands at $213.12, up 9.4%.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 28, 2022 10:25 ET (15:25 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Insulet Chart |
1 Month Insulet Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
